Patents by Inventor Chiu-Yueh Chen

Chiu-Yueh Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
    Patent number: 7943728
    Abstract: Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin ?v?3 receptor-antagonist activity and substantially reduced integrin ?llb?3 and/or ?5?1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin ?llb?3 and/or ?5?1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of ?v?3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: May 17, 2011
    Assignees: National Cheng Kung University, National Taiwan University
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Tur-Fu Huang, Wenya Huang, Chih-Hsin Tang, Chiu-Yueh Chen
  • Disintegrin variants and pharmaceutical uses thereof
    Publication number: 20080188413
    Abstract: Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin ?v?3 receptor-antagonist activity and substantially reduced integrin ?llb?3 and/or ?5?1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin ?llb?3 and/or ?5?1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of ?v?3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis.
    Type: Application
    Filed: December 20, 2007
    Publication date: August 7, 2008
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Tur-Fu Huang, Wenya Huang, Chih-Hsin Tang, Chiu-Yueh Chen